Request Demo

Last update 23 Oct 2026

Cycloserine

Last update 23 Oct 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(+)-4-amino-3-isoxazolidinone, (+)-cycloserine, alpha-Cycloserine

+ [15]

Target

ddlA

Action

inhibitors

Mechanism

ddlA inhibitors(D-alanine--D-alanine ligase A inhibitors), alr inhibitors(Alanine racemase inhibitors)

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesCongenital Disorders+ [1]

Active Indication

Pulmonary TuberculosisBronchopulmonary Dysplasia

Inactive Indication

Bipolar DisorderSchizophreniaTuberculosis, extrapulmonary+ [1]

Originator Organization

Pfizer Inc.

Active Organization

Cerovene, Inc.

McLean Hospital, Inc.

Zhejiang Hisun Pharmaceutical Co., Ltd.

+ [1]

Inactive Organization

Shandong Chengchuang Pharmaceutical R&D Co., Ltd.

License Organization

Harvard UniversityPharmacare Ltd. (South Africa)

Eli Lilly & Co.

+ [6]

Drug Highest PhaseApproved

First Approval Date

United States (29 Jun 1964),

Pulmonary Tuberculosis

RegulationSpecial Review Project (China)

Structure/Sequence

Molecular FormulaC3H6N2O2

InChIKeyDYDCUQKUCUHJBH-UWTATZPHSA-N

CAS Registry68-41-7

178

Clinical Trials associated with Cycloserine

NCT07777380

/ Not yet recruitingPhase 2IIT

One-day rTMS + D-cycloserine to Treat PTSD in Military Personnel and Veterans

The aim of this study is to examine the feasibility and tolerability of a one-day protocol of repetitive transcranial magnetic stimulation with D-cycloserine (DCS) as an augmentation strategy in military personnel and veterans who have PTSD.

Start Date01 Nov 2026

Sponsor / Collaborator

University of British Columbia

NCT07773935

/ Not yet recruitingPhase 2IIT

One-day rTMS + D-cycloserine to Treat PTSD in First Responders

Start Date01 Nov 2026

Sponsor / Collaborator

University of British Columbia

NCT07593222

/ Not yet recruitingPhase 1/2IIT

Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder

Many people with depression do not get better with standard treatments like medications or talk therapy. Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation treatment that uses magnetic pulses to stimulate areas of the brain involved in depression. One form of TMS called intermittent theta burst stimulation (iTBS) is FDA-cleared for depression and takes only 3 minutes to deliver. However, about one-third of patients do not respond to iTBS, and another one-third do not reach full remission. Improving iTBS requires a better understanding of how it works in the brain.
iTBS is thought to work by strengthening connections between brain cells, a process called synaptic plasticity. This process depends on a type of brain receptor called the NMDA receptor. Most of what researchers know about how iTBS affects these connections comes from studies of healthy people. It is not known whether iTBS works the same way in the prefrontal cortex - the brain region targeted during depression treatment - or in people who actually have depression.
This study has two phases.
In Phase 1, both healthy volunteers and people with depression will complete 4 research visits to test how iTBS changes brain activity in the prefrontal cortex and whether medications that increase or decrease NMDA receptor activity change those effects. Each visit involves active or sham (inactive) iTBS combined with one of three study medications: a placebo (inactive pill), d-cycloserine (a medication that increases NMDA receptor activity), or dextromethorphan (a medication that decreases NMDA receptor activity). Brain activity is measured before and after each TMS session using electroencephalography (EEG), a painless test that records electrical signals from the scalp through a cap placed on the head. All participants also complete a brain MRI before beginning study visits for targeting purposes.
In Phase 2, participants with depression will be offered a standard clinical course of 30 daily iTBS sessions (Monday through Friday over 6 weeks). Each session is combined with one blinded study medication (placebo, d-cycloserine, or dextromethorphan) taken daily. Brain activity measurements and standard depression and anxiety questionnaires are collected weekly throughout this phase to track how the brain changes over the course of treatment and whether those changes relate to improvements in symptoms.
Together, the two phases of this study aim to identify the brain mechanism by which iTBS works in people with depression. This knowledge could lead to more effective TMS treatments for people who have not responded to medications or other therapies.

Start Date01 Sep 2026

Sponsor / Collaborator

McLean Hospital, Inc.

[+1]

100 Clinical Results associated with Cycloserine

100 Translational Medicine associated with Cycloserine

100 Patents (Medical) associated with Cycloserine

3,556

Literatures (Medical) associated with Cycloserine

01 Feb 2027·TISSUE & CELL

Effects of decellularized biological scaffolds on motor function recovery following spinal cord injury: A systematic review and meta‑analysis

Review

Author: Ramezani, Fatemeh ; Behroozi, Zahra ; Khodaei, Mohammad Mahdi ; Haraj, Alireza ; Hamblin, Michael R

OBJECTIVE:

This systematic review and meta-analysis aimed to evaluate the efficacy of decellularized scaffolds (DCS) in improving motor function recovery in animal models of spinal cord injury (SCI).

METHODS:

A comprehensive meta-analysis was conducted on 26 individual studies investigating DCS alone and 13 studies investigating DCS combined with cells. The standardized mean difference (SMD) with 95% confidence interval (CI) was calculated to assess the overall effect size. Subgroup analyses were performed to investigate sources of heterogeneity and the impact of variables such as gender, SCI model, scaffold source, implantation time, and follow-up duration.

RESULTS:

The overall analysis revealed that implantation of DCS alone had a significant and large effect on motor function recovery compared to untreated controls (SMD = 2.6; 95% CI = 1.88-3.31; P < 0.0001). Subgroup analysis showed scaffolds derived from spinal cord tissue were significantly more effective (SMD=2.78, p < 0.0001) than those from other sources. Crucially, immediate implantation (within 30 min post-injury) yielded a strong significant effect (SMD=2.54, p < 0.0001), while a 24-hour delay abolished the significant benefit (SMD=0.903, p = 0.38). The effect was sustained over short (≤4 weeks), medium (4-8 weeks), and long-term (8 weeks) follow-ups. The combination of DCS with cell therapy showed a larger overall effect (SMD = 2.00; 95% CI = 1.21-2.79; P < 0.0001) compared with DCS alone.

CONCLUSION:

The implantation of DCS is a highly effective intervention for promoting motor recovery after SCI in animal models, especially when derived from spinal cord tissue and implanted immediately after injury.

01 Jan 2027·JOURNAL OF AFFECTIVE DISORDERS

Augmentation strategies for intravenous ketamine in treatment-resistant depression: A systematic review and meta-analysis

Review

Author: Al-Shamali, Huda F ; Jetly, Rakesh ; Janssen-Aguilar, Reinhard ; Greenshaw, Andrew ; Tanguay, Robert ; Taylor, Kaija ; Dunn, Walter ; Joseph, Jithin ; Bhat, Venkat ; Jha, Manish ; Zhao, Zixu ; Zhang, Yanbo ; Lin, Qiaowei ; Swainson, Jennifer ; Lou, Wendy

Treatment-resistant depression (TRD) affects 30-60% of individuals with major depressive disorder and carries substantial morbidity and healthcare costs. Intravenous (IV) ketamine (KET) is a rapid-acting antidepressant, but benefits are often transient, prompting augmentation to sustain efficacy or improve tolerability. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) of IV KET augmentation in adults with TRD. MEDLINE, Embase, and PsycINFO were searched through October 29, 2025. Eligible studies compared KET plus augmentation with KET plus placebo/sham or active control. Seven RCTs (N = 346) met inclusion criteria. Strategies included glutathione, riluzole, lamotrigine, lithium, D-cycloserine and ketamine combined with psychotherapy (KCP) approaches involving cognitive behavioral therapy (CBT) and automated self-association training (ASAT). Across the included trials, IV KET was associated with antidepressant improvement, although augmentation strategies generally did not demonstrate additional benefit over their respective control conditions. Pharmacological augmentation strategies did not demonstrate additional benefit at primary endpoints. KCP approaches using CBT and ASAT yielded preliminary signals of improved maintenance of antidepressant effects, although each was evaluated in a single study. An exploratory random-effects meta-analysis of seven heterogeneous comparisons found no statistically significant overall difference in depressive symptoms between augmentation and control conditions (SMD = -0.12; 95% CI, -0.37 to 0.12; p = 0.323; I² = 0.0%). No clear new safety signal emerged in the trials, although adverse-event reporting was heterogeneous across studies. Overall, low-certainty randomized evidence is insufficient to support routine augmentation of IV ketamine for TRD, highlighting the need for larger, rigorously designed trials to determine whether specific strategies can meaningfully extend ketamine's antidepressant effects.

31 Dec 2026·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Cycloserine inhibits glutamate decarboxylase from Mycobacterium tuberculosis

Article

Author: Pichová, Iva ; Dostál, Jiří ; Snášel, Jan ; Tupec, Michal ; Bulvas, Ondřej

Glutamate decarboxylase (GadB) is a pyridoxal phosphate (PLP)-dependent enzyme that contributes to intracellular pH homeostasis and supports the survival of Mycobacterium tuberculosis (Mtb) in lung tissue, granulomas, and within host macrophages. Here, we demonstrate that glutamate decarboxylase from Mycobacterium tuberculosis (MtbGadB) is a multimeric enzyme exhibiting maximal activity under acidic conditions. MtbGadB is inhibited by the clinical antibiotic d-cycloserine as well as l-cycloserine in vitro. Both cycloserine enantiomers break the internal aldimine bond between PLP and the conserved Lys277 residue, forming a previously unrecognised PLP-oxime product and subsequently inhibiting catalysis. Given that PLP-dependent enzymes are promising drug targets, understanding the chemical behaviour of PLP is essential for developing selective inhibitors.

128

News (Medical) associated with Cycloserine

19 Oct 2026

·www.biospace.com

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine

In advance of November 10, 2026 GDUFA goal date, three commercial lots of Preservative-Free Ketamine have been successfully manufactured in compliance with “Process Validation” required under FDA “Good Manufacturing Practices” (GMP). NRx has additionally received two year stability data consistent with projected room-temperature stability to three years and beyond with no need for toxic preservatives. Commercially-releasable drug supply is now on hand pending ANDA approval for this drug-shortage product. WILMINGTON, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, today announces completion of three Process Validation lots of preservative free Ketamine produced under commercial conditions in anticipation of the November 10 GDUFA (Generic Drug User Fee Amendments) Goal Date. Process Validation 1 is the final step in the drug manufacturing process required to demonstrate compliance with FDA Good Manufacturing Practices (GMP). In related developments, NRx has now completed analysis of two-year room temperature real-time stability data on preservative-free ketamine demonstrating no deterioration in purity, potency, or sterility without the need for toxic preservatives. The Company believes that these data will be consistent with a labeled shelf life of three years or longer. “Completing Process Validation and reaching two years of room-temperature stability puts NRx in position to supply this drug-shortage product the moment the FDA approves our ANDA,” said Jonathan Javitt, MD, MPH, the Company’s Chairman and CEO. “We thank our partners at Nephron Pharmaceuticals in West Columbia, South Carolina, for helping us show that sterile, preservative-free injectables can be made in America, and we look forward to supplying American hospitals and clinics.” About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. ( ), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. Notice Regarding Forward-Looking Statements The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at . Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Brian Korb Managing Partner, astr partners (917) 653-5122 brian.korb@astrpartners.com 1

Fast TrackBreakthrough TherapyNDA

15 Oct 2026

·www.prnewswire.com

Salience Researchers Contribute to Published Study Exploring Single-Day TMS for Bipolar Depression

ONE-BD case series reports promising preliminary outcomes from an innovative single-day TMS regimen for adults with bipolar I depression PLANO, Texas, Oct. 15, 2026 /PRNewswire/ -- Salience TMS Neuro Solutions is proud to announce the publication of new research examining an innovative approach to transcranial magnetic stimulation (TMS) for bipolar depression that delivers an entire course of treatment in a single day. TMS therapy is a non-invasive treatment that uses magnetic stimulation to target specific areas of the brain involved in mood. TMS systems have received FDA clearance for the treatment of major depressive disorder, anxious depression, and obsessive-compulsive disorder (OCD). Continue Reading Take a look at TMS Therapy at Salience. Speed Speed The research paper, "Real-world effectiveness of a single-day course of transcranial magnetic stimulation using an Optimized, Neuroplasticity-Enhanced regimen in Bipolar Depression (ONE-BD)," was published in Transcranial Magnetic Stimulation, the journal of the Clinical TMS Society. This report represents a collaborative effort involving investigators from Salience and research partners including Ampa Health, a Palo-Alto-based neurotechnology company building a new generation of advanced TMS systems. Bipolar depression can present significant treatment challenges, with conventional medications and psychotherapy being ineffective for many people. Yet a new generation of 'interventional psychiatry' treatments such as TMS hold the potential to succeed where conventional treatments have failed. The ONE-BD case series explored whether a single day approach could potentially reduce one of the practical barriers associated with treatment: time. Conventional TMS treatment is typically delivered through a course of once daily treatment sessions over a period of several weeks. In single-day TMS, all of the sessions are delivered at carefully spaced intervals. The ONE-BD researchers investigated a substantially accelerated approach while monitoring participants over the following weeks. The ONE-BD case series reported on treatment outcomes for 30 adults with bipolar I disorder experiencing a current depressive episode. Each patient received 20 sessions of TMS over the course of a single day, with sessions lasting 3 minutes each, and spaced approximately 20 minutes apart. Patients also received a single dose of a medication called D-cycloserine, which had been shown in previous research to enhance the treatment effects for TMS in treating other disorders. All 30 participants completed the treatment regimen. Researchers reported no serious adverse events and no switches to mania or hypomania. Patients were followed for 12 weeks, with improvements in depression symptoms observed over the weeks following treatment. At six weeks, 73.3% of patients met criteria for response and 43.3% met criteria for remission based on the 17-item Hamilton Depression Rating Scale (HDRS-17). The patients' self-rated measures of mood symptoms also showed similar patterns of improvement. The researchers characterize the findings as preliminary and note that randomized controlled studies are needed to further evaluate the approach. "Our goal is not only to provide exceptional care today, but also to participate in research that asks important questions about how treatment can continue to improve for patients in the future," said Dr. Nancy Donachie, Chief Medical Officer at Salience. For Salience, the research reflects a broader commitment to advancing the science of TMS and expanding access to safe, evidence-based treatment options for people living with treatment resistant depression and other mental health conditions. Through continued research, clinical innovation and education, Salience is working to deepen the understanding of how TMS can be used today and explore its potential to help more patients in the future. Read the full open-access study:Here To learn more on our website about ONE-BD, click here About Salience TMS Neuro Solutions Salience TMS Neuro Solutions is dedicated to advancing mental healthcare through access to TMS therapy, clinical expertise, and continued research and innovation. Since 2011, Salience has delivered more than one million TMS treatments, building extensive experience in the use of neuromodulation to help patients struggling with mental health conditions. Media Contact Salience TMS Solutions [email protected] SOURCE Salience TMS Neuro Solutions 21% more press release views with Request a Demo

Clinical ResultClinical Study

15 Oct 2026

·www.biospace.com

NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine

In advance of November 10, 2026, GDUFA goal date, all requested changes were classified as “MINOR.” NRx was requested to prepare and submit labels with the proprietary name currently under review by FDA. NRx is currently completing final manufacturing Process Validation Runs to comply with product launch requirements. WILMINGTON, Del., Oct. 15, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the receipt of a “DISCIPLINE REVIEW LETTER” from the US Food and Drug Administration requesting “MINOR” changes to the submitted label for NRx’s Preservative-Free Ketamine product. The letter requests that the Company submits sample labeling with the proposed proprietary product name currently under review in advance of the November 10, 2026, Abbreviated New Drug Application GDUFA goal date. “We at NRx deeply appreciate the engagement of the FDA Office of Generic Drugs and their focus on completing review of our product by the GDUFA goal date,” said Jonathan Javitt, MD, MPH, the Company’s Chairman and CEO. “The supply of ketamine in the United States has been primarily from overseas manufacture and American hospitals and doctors have been plagued by repeated shortages of this critically important drug. We look forward to demonstrating that manufacture of drugs such as this can successfully be re-shored to the United States. We believe that making a preservative-free preparation of ketamine is important for patients and appreciate the willingness of FDA to work with us on an appropriate product name.” About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. ( ), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. Notice Regarding Forward-Looking Statements The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at . Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Brian Korb Managing Partner, astr partners (917) 653-5122 brian.korb@astrpartners.com

Fast TrackNDABreakthrough Therapy

100 Deals associated with Cycloserine

External Link

KEGG	Wiki	ATC	Drug Bank
D00877	Cycloserine	J04AB01	DB00260

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pulmonary Tuberculosis	United States	Cerovene, Inc.	29 Jun 1964

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchopulmonary Dysplasia	Phase 2	United States	McLean Hospital, Inc.	10 Jun 2026
Bipolar Disorder	Phase 1	-	McLean Hospital, Inc.	27 Sep 2015
Schizophrenia	Phase 1	-	McLean Hospital, Inc.	27 Sep 2015
Tuberculosis, extrapulmonary	Phase 1	China	Shandong Chengchuang Pharmaceutical R&D Co., Ltd.	20 Feb 2012
Urinary Tract Infections	Phase 1	China	Shandong Chengchuang Pharmaceutical R&D Co., Ltd.	20 Feb 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02983734 (GWDCS, CTgov)	Phase 2	Persian Gulf Syndrome	22	D-cycloserine (D-cycloserine (DCS))	wssmmalpfr(dbmzpgmayn) = ujvwvclhsm linfbaeuir (phpggpyjex, 4) View more	-	09 Sep 2026
				Placebo (Placebo)	wssmmalpfr(dbmzpgmayn) = fbmqjftwmb linfbaeuir (phpggpyjex, 5) View more
NCT03535688 (CTgov)	Phase 2	Low Back Pain	203	D-cycloserine (D-cycloserine)	lhbsaaywas(manjpbswno) = vgczqyfmgb ymbjytweon (iokbjwqnfb, 1.94) View more	-	04 May 2026
				Placebo (Placebo)	lhbsaaywas(manjpbswno) = wrasyokdmz ymbjytweon (iokbjwqnfb, 2.27) View more
ERS2023	Not Applicable	-	250	bedaquiline+levofloxacin+linezolid+clofazimine+cycloserine/delamanid	grnuvkzeqg(pmaokvjtzy) = jbbyuysguu sxejikcpof (oljkkvkdjw, 1.4 - 2.6)	Positive	09 Sep 2023
NCT02385266 (UCPPS, CTgov)	Phase 4	Chronic pelvic pain syndrome	24	D-Cycloserine (D-Cycloserine and Acetominophen)	jgvsnzytlm(lbugixaexa) = gpeocrclht xofzjsgrbw (bafxocacwx, 2.6) View more	-	17 May 2023
				Placebo (for D-cycloserine) (Placebo and Acetominophen)	jgvsnzytlm(lbugixaexa) = tulaqqrkev xofzjsgrbw (bafxocacwx, 1.5) View more
NCT03937596 (Pubmed \| JAMA Psychiatry)	Phase 2	Depressive Disorder, Major	50	iTBS plus placebo	gnwoulvtsz(uovtzycvqa) = vsfghmeiap bxcwidxbdj (lhoincvcfj ) View more	Positive	12 Oct 2022
				iTBS plus D-cycloserine (100 mg)	gnwoulvtsz(uovtzycvqa) = nbnadpzctj bxcwidxbdj (lhoincvcfj ) View more
NCT00875342 (CTgov)	Not Applicable	Stress Disorders, Post-Traumatic	41	DCS (D-cycloserine)	krnndrhucb(rcdhripsin) = qxvzjecpcr deljeazbtn (ibbgwzynxt, 32.31) View more	-	16 Aug 2021
				Placebo (Placebo)	krnndrhucb(rcdhripsin) = ogbknxcbjm deljeazbtn (ibbgwzynxt, 25.06) View more
NCT01944423 (DCS/PSRT, CTgov)	Early Phase 1	Panic \| Nicotine Dependence	53	Panic and Smoking Reduction Treatment+Nicotine replacement therapy+d-cycloserine (PSRT_DCS)	xzdqdlkmku = aokpbqpytw imeaomryoa (ubamnbygvd, hyjohuzipp - czmmdfmkhu) View more	-	19 May 2021
				Pill Placebo+Nicotine replacement therapy (PSRT_PBO)	xzdqdlkmku = cswofearag imeaomryoa (ubamnbygvd, hmfzgpblpt - czlldyukwy) View more
NCT02066792 (CTgov)	Early Phase 1	Phobia, Social	152	Cognitive Behavioral Therapy+D-Cycloserine (Tailored Post-Session DCS)	dvzxgivjdz(faamkpshcq) = epkwgzbogh ngvvzeuebm (cydcvqbotx, .13) View more	-	09 Jun 2020
				Cognitive Behavioral Therapy+D-Cycloserine (Pre-Session DCS)	dvzxgivjdz(faamkpshcq) = xwzxtmgveq ngvvzeuebm (cydcvqbotx, .13) View more
NCT01680107 (d-cycloserine Augmented CBT for Panic Disorder, Pubmed \| Behav Res Ther)	Phase 3	Anxiety Disorders	33	d-cycloserine	nwkcezfjde(xuygckgxhr) = ciebhkhxsq ctzomtgjuk (lwzqumintd )	-	01 Jun 2020
				Placebo	nwkcezfjde(xuygckgxhr) = atdllydrhh ctzomtgjuk (lwzqumintd )
NCT02687165 (PTLS, CTgov)	Not Applicable	Post-Lyme Disease Syndrome \| Chronic Pain	4	Milnacipran+D-cycloserine (Milnacipran Augmented by D-cycloserine)	dtolnjdtqa(vttqczhivf) = ywbqqogzdm pxvgizpmvx (humwbcplry, ehgpzjheka - xuhhdfvqqv) View more	-	01 Jun 2020
				Milnacipran+D-cycloserine (Milnacipran Augmented by Placebo)	dtolnjdtqa(vttqczhivf) = wtyweglpqo pxvgizpmvx (humwbcplry, xdaqxomlow - pkxnttndmg) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis